Stem cell science specialist Cellartis AB could earn as much as €100 million (US$125 million) in development and sales milestones from a cell therapy collaboration in diabetes with Novo Nordisk A/S and Lund University in Sweden. (BioWorld Today) Read More
No Abstract BioWorld Today CorrespondentLONDON - Apitope Ltd. was forced to look beyond the UK to raise €10 million (US$12.5 million) from Belgian investors in its first formal venture capital funding round. The money will enable the company to carry out a Phase II proof-of-concept trial of its peptide-based immunotherapy for multiple sclerosis and to commercialize a diagnostic for identifying the disorder in its early stages. Read More
